Abstract
The Ras superfamily of small monomeric GTPases includes some of the most prominent cancer targets for which no selective therapeutic agent has yet been successfully developed. The turn of the millennium saw a resurgence of efforts to target these enzymes using new and improved biophysical techniques to overcome the perceived difficulties of insurmountably high affinity for guanosine nucleotides and flat, flexible topology lacking suitable pockets for small molecule inhibitors. Further, recent investigations have begun to probe the dynamic conformational status of GTP-bound Ras, opening up new mechanisms of inhibition. While much of the literature has focused on the oncogenic Ras proteins, particularly K-Ras, these represent only a small minority of therapeutically interesting targets within the superfamily; for example, the Rab GTPases are the largest subfamily of about 70 members, and present an as yet untapped class of potential targets. The present review documents the key methodologies employed to date in structure-guided attempts to drug the Ras GTPases, and forecasts their transferability to other similarly challenging proteins in the superfamily.
Keywords: Cancer, Fragment-based drug design, GTPase, Structure-based drug design, Rab, Ras, X-ray crystallography.
Current Topics in Medicinal Chemistry
Title:Direct Targeting of the Ras GTPase Superfamily Through Structure- Based Design
Volume: 17 Issue: 1
Author(s): Wenye Zhao, Mostafa Jamshidiha, Thomas Lanyon-Hogg, Chiara Recchi, Ernesto Cota and Edward W. Tate
Affiliation:
Keywords: Cancer, Fragment-based drug design, GTPase, Structure-based drug design, Rab, Ras, X-ray crystallography.
Abstract: The Ras superfamily of small monomeric GTPases includes some of the most prominent cancer targets for which no selective therapeutic agent has yet been successfully developed. The turn of the millennium saw a resurgence of efforts to target these enzymes using new and improved biophysical techniques to overcome the perceived difficulties of insurmountably high affinity for guanosine nucleotides and flat, flexible topology lacking suitable pockets for small molecule inhibitors. Further, recent investigations have begun to probe the dynamic conformational status of GTP-bound Ras, opening up new mechanisms of inhibition. While much of the literature has focused on the oncogenic Ras proteins, particularly K-Ras, these represent only a small minority of therapeutically interesting targets within the superfamily; for example, the Rab GTPases are the largest subfamily of about 70 members, and present an as yet untapped class of potential targets. The present review documents the key methodologies employed to date in structure-guided attempts to drug the Ras GTPases, and forecasts their transferability to other similarly challenging proteins in the superfamily.
Export Options
About this article
Cite this article as:
Zhao Wenye, Jamshidiha Mostafa, Lanyon-Hogg Thomas, Recchi Chiara, Cota Ernesto and Tate W. Edward, Direct Targeting of the Ras GTPase Superfamily Through Structure- Based Design, Current Topics in Medicinal Chemistry 2017; 17 (1) . https://dx.doi.org/10.2174/1568026616666160719165633
DOI https://dx.doi.org/10.2174/1568026616666160719165633 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
In Vitro Evidence for Competitive TSPO Binding of the Imaging Biomarker Candidates Vinpocetine and Two Iodinated DAA1106 Analogues in Post Mortem Autoradiography Experiments on Whole Hemisphere Human Brain Slices
Current Radiopharmaceuticals Fluorescence Imaging in Cancerology
Current Molecular Imaging (Discontinued) MICA Gene and Relevance to Immune Responses in Organ Transplants and Inflammatory, Tumoral and Autoimmune Diseases
Current Immunology Reviews (Discontinued) In Vitro Synergistic Interaction between DTA0100 and Radiation in Human Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Diagnosis and Management of Endocrine Hypertension in Children and Adolescents
Current Pharmaceutical Design Nanosponges Encapsulated Phytochemicals for Targeting Cancer: A Review
Current Drug Targets Pannexin Channels: The Emerging Therapeutic Targets
Current Drug Targets Antitumor Therapeutic Strategies Based on the Targeting of Epidermal Growth Factor-Induced Survival Pathways
Current Drug Targets Central Nervous System Vasculitis: Still More Questions than Answers
Current Neuropharmacology Insulin Resistance, Oxidative Stress and Cardiovascular Complications: Role of Sirtuins
Current Pharmaceutical Design STAT3 as a Therapeutic Target for Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Brain Drug Delivery System: An Overview
Current Drug Therapy Biodistribution and Pharmacokinetics of I-131 Labelled 4- Iodophenylacetic Acid
Current Radiopharmaceuticals Gliomas: Current Issues in Diagnosis and Treatment
Current Medical Imaging Targeting p73 - a Potential Approach in Cancer Treatment
Current Pharmaceutical Design Photo- and Sono-Dynamic Therapy: A Review of Mechanisms and Considerations for Pharmacological Agents Used in Therapy Incorporating Light and Sound
Current Pharmaceutical Design Peptide Therapeutics in Neurodegenerative Disorders
Current Medicinal Chemistry Statins, Mevalonate Pathway and its Intermediate Products in Placental Development and Preeclampsia
Current Molecular Pharmacology Lectins in Human Cancer: Both a Devil and an Angel?
Current Protein & Peptide Science Late Effects in Survivors of Childhood CNS Tumors: Review of Results From the Two Largest Survivorship Cooperative Groups
Current Cancer Therapy Reviews